CD274 and head and neck squamous cell carcinoma: Besides, a phase Ib/IIa trial with similar design combining MEDI0457 (an HPV vaccine plus IL-12) with durvalumab (a PD-L1 blocking antibody) in patients with recurrent/metastatic HPV+ HNSCC reported an objective response rate (ORR) of 27.6% and a median OS of 29.2 months40.